Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17416191 | 1.00 | LMNA (0.36) | LMNAKDM4EUGCGPRMT5WDR77 | |
| SCHEMBL17416118 | 0.81 | KDM4E (0.35) | KDM4EADRB3ADRB1 | |
| SCHEMBL17416215 | 0.81 | KDM4E (0.35) | KDM4EADRB3ADRB1 | |
| SCHEMBL17415945 | 0.80 | KDM4E (0.35) | KDM4ETLR2ADRB3ADRB1 | |
| SCHEMBL17416189 | 0.80 | KDM4E (0.35) | KDM4ETLR2ADRB3ADRB1 | |
| SCHEMBL17416150 | 0.80 | KDM4E (0.35) | KDM4E | |
| SCHEMBL17416207 | 0.80 | KDM4E (0.35) | KDM4E | |
| SCHEMBL17415936 | 0.79 | KDM4E (0.34) | KDM4E | |
| SCHEMBL17416202 | 0.79 | KDM4E (0.34) | KDM4E | |
| SCHEMBL25869491 | 0.79 | USP2 (0.48) | LMNAKDM4EADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204076-A1 | SYNTHESIS AND USE OF AMINO LIPIDS | SCREENFECT GMBH (DE) | 2017-07-20 | — | — | US | disclosed |
| US-20170204076-A1 | SYNTHESIS AND USE OF AMINO LIPIDS | SCREENFECT GMBH (DE) | 2017-07-20 | — | — | US | disclosed |
| US-20170204076-A1 | SYNTHESIS AND USE OF AMINO LIPIDS | SCREENFECT GMBH (DE) | 2017-07-20 | — | — | US | disclosed |
| EP-2966068-A1 | Synthesis and use of amino lipids | Incella GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966068-A1 | Synthesis and use of amino lipids | Incella GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204076-A1 | SYNTHESIS AND USE OF AMINO LIPIDS | ACSL4, PYM1, LPAR4 | LMNA 1388/4885KDM4E 389/4885UGCG 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.